SynthesisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026
Treatments for molluscum contagiosum: A systematic review.
Synthesis in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reverse vaccinology and immunoinformatics identify multi-epitope vaccine candidates against molluscum contagiosum virus.Biology methods & protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molluscum contagiosum (MC) is a viral skin infection that poses significant physical and psychosocial burdens, particularly in pediatric and immunocompromised populations. Despite the availability of various treatment options, comparative efficacy and safety data remain limited. This systematic review, conducted in accordance with PRISMA guidelines, evaluates and compares the efficacy, safety, recurrence, and adverse effects of MC treatments. A total of 89 studies encompassing 12,955 participants were analyzed. Curettage, potassium hydroxide (KOH), autoinoculation, and podophyllotoxin demonstrated high clearance rates (97.8%, 73.8%, 79.4%, and 75.0%, respectively) with minimal local side effects. Cryotherapy and laser therapies offered rapid lesion resolution though laser treatment was associated with more discomfort and higher cost. Emerging therapies such as berdazimer gel demonstrated favorable safety profiles, particularly for pediatric patients, while intralesional immunotherapies like Candida and MMR vaccine showed encouraging results in patients with persistent or recurring lesions. The management of MC requires an individualized approach, balancing efficacy, safety, and patient-specific factors such as age, lesion severity, and immune status. Cantharidin, KOH, cryotherapy, autoinoculation, and podophyllotoxin offer high clearance rates, with immunotherapies and lasers offering additional options for resistant cases. Further standardized trials are needed to optimize treatment strategies and long-term recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.